Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07471139 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SWITCH: Apixaban vs Vitamin K in HM3

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 32 days later Jun 2029 → Aug 2029
See other at-risk trials from Columbia University

Record History

  1. Start date: Jun 2026 to Aug 2026 Primary and study completion pushed from Jun 2029 to Aug 2029v2 Show 1 more changeShow less
    • Primary and study completion pushed from Jun 2029 to Aug 2029
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Columbia University
302 trials monitored
See 23 trials at risk
Stroke
3,289 trials monitored
See 141 trials at risk
Heart Failure
1,871 trials monitored
See 100 trials at risk
This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced heart failure who are chronically supported by a HeartMate 3 Left Ventricular Assist Device for 3 months.
Trial Details
NCT Number NCT07471139
Lead Sponsor Columbia University
Conditions LVAD (Left Ventricular Assist Device) Thrombosis, Heart Failure, Bleeding, Thrombosis; Artery, Stroke, Heart Transplant
Enrollment 460 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov